The CST Complex Mediates End Protection at Double-Strand Breaks and Promotes PARP Inhibitor Sensitivity in BRCA1-Deficient Cells

Graphical Abstract

Highlights
- PARP inhibitor resistance screens independently identify loss of CTC1 as major hit
- The CST complex promotes PARP inhibitor sensitivity in BRCA1-deficient cells
- Depletion of CTC1 restores end resection in BRCA1-deficient cells
- CTC1 facilitates double-strand break repair via canonical non-homologous end joining

Authors
Marco Barazas, Stefano Annunziato, Stephen J. Pettitt, ... Christopher J. Lord, Jos Jonkers, Sven Rottenberg

Correspondence
j.jonkers@nki.nl (J.J.), sven.rottenberg@vetsuisse.unibe.ch (S.R.)

In Brief
Using CRISPR/SpCas9-based loss-of-function screens, Barazas et al. show that loss of the CTC1-STN1-TEN1 (CST) complex promotes PARP inhibitor resistance in BRCA1-deficient cells. Mechanistically, the CST complex maintains double-strand break end stability in addition to its role in protecting telomeric ends.
The CST Complex Mediates End Protection at Double-Strand Breaks and Promotes PARP Inhibitor Sensitivity in BRCA1-Deficient Cells

Marco Barazas,1 Stefano Annunziato,1 Stephen J. Pettitt,2 Inge de Krijger,3 Hind Ghezraoui,4 Stefan J. Roobol,5,6 Catrin Lutz,1 Jessica Frankum,1 Fei Fei Song,2 Rachel Brough,2 Bastiaan Evers,7 Ewa Gogola,1 Jinhyuk Bhin,1,7 Marieke van de Ven,1,8 Dik C. van Gent,9 Jacqueline J.L. Jacobs,3 Ross Chapman,4 Christopher J. Lord,2 Jos Jonkers,1,* and Sven Rottenberg1,9,10,*

1Division of Molecular Pathology, Oncode Institute, the Netherlands Cancer Institute, 1066CX Amsterdam, the Netherlands
2The CRUK Gene Function Laboratory and Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London SW3 6JB, UK
3Division of Oncogenomics, the Netherlands Cancer Institute, 1066CX Amsterdam, the Netherlands
4Genome Integrity Laboratory, Wellcome Centre for Human Genetics, University of Oxford, Oxford OX3 7BN, UK
5Department of Genetics, Erasmus University Medical Center, Rotterdam, the Netherlands
6Department of Radiology and Nuclear Medicine, Erasmus University Medical Center, Rotterdam, the Netherlands
7Division of Molecular Carcinogenesis, the Netherlands Cancer Institute, 1066CX Amsterdam, the Netherlands
8Mouse Clinic for Cancer and Aging Research (MCCA), Preclinical Intervention Unit, the Netherlands Cancer Institute, 1066CX Amsterdam, the Netherlands
9Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, Bern, Switzerland
10Lead Contact
*Correspondence: j.jonkers@nki.nl (J.J.), sven.rottenberg@vetsuisse.unibe.ch (S.R.)
https://doi.org/10.1016/j.celrep.2018.04.046

SUMMARY

Selective elimination of BRCA1-deficient cells by inhibitors of poly(ADP-ribose) polymerase (PARP) is a prime example of the concept of synthetic lethality in cancer therapy. This interaction is counteracted by the restoration of BRCA1-independent homologous recombination through loss of factors such as 53BP1, RIF1, and REV7/MAD2L2, which inhibit end resection of DNA double-strand breaks (DSBs). To identify additional factors involved in this process, we performed CRISPR/SpCas9-based loss-of-function screens and selected for factors that confer PARP inhibitor (PARPi) resistance in BRCA1-deficient cells. Loss of members of the CTC1-STN1-TEN1 (CST) complex were found to cause PARPi resistance in BRCA1-deficient cells in vitro and in vivo. We show that CSTC1 depletion results in the restoration of end resection and that the CST complex may act downstream of 53BP1/RIF1. These data suggest that, in addition to its role in protecting telomeres, the CST complex also contributes to protecting DSBs from end resection.

INTRODUCTION

The synthetic lethal interaction between BRCA1 deficiency and poly(ADP-ribose) polymerase (PARP) inhibition is a well-established therapeutic paradigm with encouraging response rates in the clinic (Lord and Ashworth, 2017). This has resulted in the recent regulatory approval of three PARP inhibitors (PARPis) for the treatment of serous ovarian cancers and one PARPi, olaparib, for the treatment of BRCA-mutated, HER2-negative breast cancers. Moreover, the BRCA-PARP paradigm might be extended beyond breast and ovarian cancer because recent clinical studies indicate that a subset of prostate cancers harbor a homologous recombination (HR) defect and, hence, might benefit from olaparib treatment (Mateo et al., 2015; Pritchard et al., 2016).

Despite this success, long-lasting clinical response rates in patients with advanced disease are limited by the development of resistance, the mechanisms of which have not been fully elucidated. A major class of resistance mechanisms centers on re-expression of functional BRCA1 or BRCA2 protein, either through promoter demethylation, genetic reversion, or gene fusions (Patch et al., 2015; Swisher et al., 2008; Ter Brugge et al., 2016). However, our previous work also identified the existence of additional BRCA1-independent resistance mechanisms in the K14cre; Brca1+/−;p53+/− (KB1P) genetically engineered mouse model of hereditary breast cancer (Liu et al., 2007). In this model, re-expression of functional BRCA1 is excluded because of the large, engineered, intragenic Brca1 deletion, which spans multiple exons. Despite the absence of functional BRCA1 restoration, KB1P tumors acquired resistance to PARPi treatment. In addition to activation of the P-glycoprotein drug efflux transporter (Rottenberg et al., 2008), the BRCA1-independent resistance mechanisms in KB1P tumors predominantly involved the partial restoration of HR activity through re-wiring of the DNA damage response (DDR); for example, by loss of 53BP1 (Bouwman et al., 2010; Bunting et al., 2010; Jaspers et al., 2013). These seminal findings have spurred a number of studies in which additional downstream antagonists of end resection were identified, including RIF1 (Chapman et al., 2013; Di Virgilio et al., 2013; Escribano-Diaz...
etal., 2013; Zimmermann et al., 2013) and REV7/MAD2L2 (Boersma et al., 2015; Xu et al., 2015). However, the currently known resistance factors cannot explain all PARPi-resistant cases, suggesting that additional proteins functioning in this pathway remain to be identified. Moreover, although the loss of resection antagonists partially restores end resection of DNA double-strand breaks (DSBs), none of these factors have direct functions in DNA metabolism, raising the question of how DNA metabolism at DSBs might be altered to stimulate end resection.

The function of the 53BP1 pathway is not exclusive to canonical DSB repair, but it also acts on telomeres (Panier and Boulton, 2014). Because telomere ends resemble DSBs located at chromosomal termini, cells have evolved several mechanisms to protect telomeres from DSB end processing and chromosome end-to-end fusions (Sfeir and de Lange, 2012). Mammalian telomeres consist of TTAGGG repeats ending with a single-strand G-rich overhang. The single-stranded DNA (ssDNA) overhang is crucial in telomere maintenance because it is required for the formation of the T-loop structure (Makarov et al., 1997; McElligott and Wettling, 1997). Notably, excessive resection of telomere ends is inhibited by the action of the shelterin complex and by the 53BP1 pathway (Lazzaroni-Denchi and Sfeir, 2016; Sfeir and de Lange, 2012).

Besides the mechanisms that have evolved to protect telomeric overhangs from excessive processing, it has recently been shown that the RPA-like CTC1-STRN1-TEN1 (CST) complex is able to localize to telomeric ssDNA and mediate a fill-in reaction executed by polymerase-alpha (POLA) to buffer resection activity (Feng et al., 2017; Miyake et al., 2009; Wu et al., 2012). Notably, it was demonstrated that the binding of the CST complex to ssDNA is not particularly sequence-specific, although a partial preference for G-rich regions has been described (Hom and Wuttke, 2017; Miyake et al., 2009). Additionally, CST components do not localize exclusively to telomeres (Miyake et al., 2009). This might argue that the CST complex also has non-telomeric functions.

In this study, three independent forward genetic CRISPR/SpCas9-based loss-of-function screening approaches were employed to identify factors that induce PARPi resistance in BRCA1-deficient cells. Together, these screens identified that defects in Ctc1, or its CST complex members Stn1 or Ten1, suppress the synthetic lethal interaction between BRCA1 and PARP inhibition. Inactivation of CTC1 is sufficient to drive PARPi resistance in vivo. Depletion of CTC1 increased end resection activity and subsequently restored RAD51 focus formation upon ionizing radiation (IR)-induced DNA damage, providing a mechanistic basis for these observations. Moreover, the CST complex facilitates canonical non-homologous end joining (c-NHEJ)-driven repair. Together, these data demonstrate that the CST complex plays a more global role in DNA repair beyond the protection of telomeres.

**RESULTS**

**Forward Genetic CRISPR/SpCas9 Screens Identify Selective Enrichment for Loss of CTC1 during PARPi Treatment in BRCA1-Deficient Cells**

To identify factors that modulate the synthetic lethal interaction between BRCA1 and PARP, we carried out three independent forward genetic loss-of-function CRISPR/SpCas9 screens (Figure 1). All screens were analyzed by harvesting cells before and after PARPi treatment, after which single guide RNA (sgRNA) sequences were amplified from genomic DNA by PCR and analyzed by next-generation sequencing. The screening data were processed by the model-based analysis of genome-wide CRISPR-Cas9 knockouts (MAgeCK) or the drugZ algorithm (Li et al., 2014; Wang et al., 2017), and the results were sorted on positive selected gene ranks to allow comparison across screens. Additional experimental details are provided in the Supplemental Experimental Procedures.

The first PARPi resistance screen was performed in SpCas9-expressing KB1P-G3 mouse mammary tumor cells (Jaspers et al., 2013) using a custom-made lentiviral sgRNA library targeting 1,752 DDR-related genes (Table S1) cloned into the doxycycline-inducible pLenti-sgRNA-tetR-T2A-PuroR vector (Prahallad et al., 2015). The screen was performed at 100× coverage, and cells were selected with two different PARPis, olaparib and AZD2461 (Oplustil O’Connor et al., 2016), at the approximate inhibitory concentration 90 (IC90) for 14 days (Figure 1A). Although sgRNAs targeting Tp53bp1 were deliberately removed from the library to avoid the possibility that this potent PARPi resistance factor might obscure the effects of other genes, its upstream regulatory factor Rnf8 scored among the top genes (Figure 1B).

The second PARPi resistance screen was performed in SpCas9-expressing Brca1−/−;Tp53−/− mouse embryonic stem cells (mESCs) infected with a genome-wide lentiviral sgRNA library targeting 19,150 genes (Koike-Yusa et al., 2014). This screen was performed at 75× coverage in two independent transductions, and cells were selected with olaparib at a concentration of 15 nM for 10 days. As expected, Tp53bp1 and Rnf8 scored among the top genes and ranked #1 and #15, respectively (Figure 1C).

A third PARPi resistance screen was performed in Brca12288delT mutant SUM149PT human breast cancer cells (Elstrodt et al., 2006). SUM149PT cells expressing doxycycline-inducible SpCas9 were lentivirally infected with a genome-wide lentiviral sgRNA library targeting 18,010 genes (Tzelepis et al., 2016). This screen was performed at 1,000× coverage, and cells selected in the presence of doxycycline plus 100 nM talazoparib for 2 weeks. The screen was dominated by sgRNAs targeting PARP1, the drug target of talazoparib. Although PARP1 loss is expected to be lethal in BRCA1-deficient cells, the selection for PARP1 loss in SUM149PT cells might be attributed to residual BRCA1 activity, which might enable cell survival in the absence of PARP1 (Pettitt et al., 2017; Wang et al., 2016). Moreover, TP53BP1 scored among the top enriched genes and ranked #7 (Figure 1D).

The results from these three independent screens were collated to identify consistent outliers. The top 20 genes were selected from the DDR-focused library screen in KB1P-G3 cells. Because the genome-wide libraries contain about 10-fold more genes than the DDR-focused library, the top 200 genes were selected from the mESC and SUM149PT screens, and these were plotted in a Venn diagram (Figure 1E). Notably, Ctc1 was the only gene that consistently scored in all three screens (ranked #10, #39, and #39 in the KB1P-G3, mESC, and...
Moreover, Stn1 (also known as Obfc1) scored in two of three screens. These results caught our attention because both CTC1 and STN1 are members of the CST complex. Although the CST complex has known functions in telomere metabolism, these PARPi resistance screens might point toward non-telomeric functions of the CST complex. Because Ctc1 was a top hit in all three independent screens in both mouse and human cells, we prioritized this gene for further validation.

**Depletion of CTC1 Suppresses the Synthetic Lethal Interaction between BRCA1 Deficiency and PARP Inhibition**

To validate the effect of CTC1 on PARPi sensitivity in BRCA1-deficient cells, we transfected KB1P-G3 cells with pX330 vectors containing three sgRNAs targeting a putative oligonucleotide-binding (OB) fold domain of Ctc1 (Figure 2A). The polyclonal targeted populations were efficiently modified for the target site (Figures 2B–2D), as shown by TIDE (tracking of insertions or deletions [indels] by decomposition) analysis (Brinkman et al., 2014). These populations were subsequently treated with olaparib (75 nM) or AZD2461 (250 nM), the same concentrations as used for the screen. As expected, parental KB1P-G3 cells or KB1P-G3 cells targeted by a non-targeting sgRNA (sgNT) showed high sensitivity to PARPi treatment. In contrast, Ctc1-targeted cells showed resistance to treatment, indicating that depletion of CTC1 suppresses the synthetic lethal interaction between BRCA1 deficiency and PARP inhibition (Figures 2E and F). This could not be attributed to an effect on cell proliferation because we observed no difference in the doubling time upon depletion of CTC1 (Figure 2G).

We next investigated whether Ctc1-mutated cells would be specifically selected out from a mixed population by prolonged PARPi treatment. A competition assay was performed in which...
Figure 2. Depletion of CTC1 Suppresses the Synthetic Lethal Interaction between BRCA1 Deficiency and PARP Inhibition

(A) Schematic overview of the Ctc1 gene, in which putative OB fold domains and sgRNA target locations are indicated (adapted from Miyake et al., 2009).

(B–D) KB1P-G3 cells were transfected with pX330puro vectors containing the indicated sgRNAs, and the target region was PCR-amplified to verify allele modification using TIDE software.

(E) The indicated Ctc1-mutated KB1P-G3 cell lines were plated for clonogenic growth upon olaparib (75 nM) or AZD2461 (250 nM) treatment. Three independent experiments were performed, and each condition was plated in triplicate. One representative well per condition is shown for each independent experiment.

(F) Quantification of crystal violet staining in (E). Data were plotted relative to the growth of untreated sgNT cells and are presented as mean ± SD (n = 3 independent experiments). Significance was calculated by two-way ANOVA with Dunnett’s multiple comparisons test (***/p = 0.0001).

(G) Relative cell proliferation was determined by IncuCyte Zoom Live – Cell Analysis System measurements. Each data point represents the average of three independent experiments, and in each experiment, six replicate wells were measured and averaged. Data represent mean ± SD (n = 3). Doubling times (exponential growth equation) were calculated using GraphPad software, and significance was calculated by one-way ANOVA with Dunnett’s multiple comparisons test.

(H and I) SpCas9-expressing KB1P-G3 cells were transduced with doxycycline-inducible pLenti-sgRNA-tetR-T2A-PuroR vectors containing the indicated sgRNAs. Polyclonal populations were plated for clonogenic growth with or without AZD2461 (250 nM) (H). Cells were passaged every 10 days for a total of three times. At the endpoint, wells were fixed and stained with crystal violet, and allele distributions were determined from each condition using TIDE software (I).

(J) KB1P-G3 cells were transfected with pX330puro vectors containing sgRNAs targeting Stn1 and Ten1 and cultured in the presence or absence of 75 nM olaparib as in (E). Data were analyzed as in (F) and reflect at least two independent experiments.
the evolution of polyclonal populations was monitored by the TIDE algorithm to quantify changes in allele distributions. sgRNAs were cloned in the pLenti-sgRNA-tetR-T2A-Puro vector and introduced in SpCas9-expressing KB1P-G3 cells by lentiviral transduction. The population was mutagenized by doxycycline-induced expression of the sgRNA for 5 days, after which cells were plated without doxycycline for clonogenic growth. After 10 days of culture in the presence or absence of AZD2461, the cells were harvested and re-plated at equal amounts every 10 days for an additional two rounds, resulting in a total treatment duration of 30 days. Although non-transduced cells or cells transduced with a non-targeting sgRNA were effectively killed by this prolonged treatment, Ctc1-targeted cells survived (Figure 2H). This coincided with an enrichment of Ctc1 frameshift mutations compared with untreated populations, which were kept in culture for the same duration (Figure 2I).

To study whether this effect is CTC1-specific or a feature of the CST complex, we genetically inactivated the other two CST complex members Stn1 and Ten1, and treated these cells with olaparib under the same conditions as used for Ctc1. CRISPR/SpCas9-mediated disruption of Stn1 or Ten1 also induced PARPi resistance, recapitulating the effect of Ctc1 (Figure 2J). This is consistent with the identification of STN1 in the PARPi resistance screens (Figure 1E) and shows that PARPi sensitivity is modulated by all CST complex members rather than CTC1 alone.

These data were corroborated in Brca1<sup>−/−</sup>;Trp53<sup>−/−</sup> mESCs in which CRISPR/SpCas9-assisted inactivation of Ctc1 increased survival upon olaparib treatment, which was accompanied by a selection for frameshifting alleles (Figures S1A and S1B). Furthermore, we targeted the CST complex members in R26<sup>CreERT2;Brca1<sup>Sc0/a</sup> mESCs, which harbor a selectable conditional Brca1<sup>Sc0</sup> allele that can be inactivated by CreERT2 through the addition of 4-hydroxytamoxifen (4-OHT) (Bouwman et al., 2010). Although 4-OHT-induced inactivation of BRCA1 caused lethality in untransduced R26<sup>CreERT2;Brca1<sup>Sc0/a</sup> mESCs, clonal outgrowth was observed for cells depleted of CTC1, STN1, or TEN1 (Figure 3A). Complete switching of the conditional Brca1<sup>Sc0</sup> allele in the surviving population was confirmed by PCR, ruling out that clonal outgrowth was due to a non-recombinant Brca1<sup>Sc0</sup> allele (Figure 3B). Finally, depletion of CTC1 in SUM149PT cells enhanced cell survival in the presence of talazoparib, as did depletion of 53BP1 (Figure 3C), confirming that this effect was not restricted to mouse cells.

In summary, we confirmed that the CST complex promotes PARPi-induced cell lethality in BRCA1-deficient cells. We therefore looked at the role of the CST complex in preventing global DNA damage, focusing on CTC1.

**CTC1 Antagonizes End Resection at Non-Telomeric DSBs**

During the repair of DSBs, a critical decision is made between initiating repair via NHEJ or via HR, which both require distinct end processing. This decision is tightly balanced by end protection factors, such as 53BP1 or RIF1, which antagonize resection to direct repair via NHEJ, and BRCA1, which promotes end resection to direct repair via HR (Chapman et al., 2013; Daley and Sung, 2014; Escribano-Díaz et al., 2013; Feng et al., 2015;
Panier and Boulton, 2014). It was previously shown that the end resection defect in BRCA1-deficient cells can be rescued via loss of 53BP1, and this also rescued cell lethality induced by BRCA1 loss (Bouwman et al., 2010; Bunting et al., 2012). Hence, the finding that loss of the CST complex (Figure 3A) rescued BRCA1 lethality points toward a potential inhibitory role in DSB end resection. Moreover, depletion of CTC1 did not induce PARPi resistance in BRCA2-deficient cells (Figures S2A and S2B), which is in line with a possible role of the CST complex upstream of BRCA2.

DSB end resection produces ssDNA overhangs, which are protected from nucleolytic degradation and the formation of secondary structures by the coating of RPA. Therefore, we visualized RPA loading in response to α-particle-induced DNA damage by immunofluorescence as a readout for end resection (Stap et al., 2008). In line with previous studies (Tkáč et al., 2016; Xu et al., 2015), KB1P-G3 tumor cells showed a clear resection defect that was partially restored in Ctc1-mutated KB1P-G3 cells but not in sgNT-transfected control cells (Figures 4A and 4B).

We next investigated whether CTC1 loss affects the recruitment of DDR factors to sites of irradiation-induced DNA damage. CRISPR/SpCas9-targeted KB1P-G3 cells were either left untreated or treated with 10 Gy of ionizing radiation (IR), which potently induced 2112 Cell Reports 23, 2107–2118, May 15, 2018
yH2AX foci (Figures 4C and 4D; Figures S3A and S3B). Although depletion of 53BP1 in KB1P-G3 cells abolished the formation of IR-induced 53BP1 and RIF1 foci, these effects were not observed in CTC1-depleted cells (Figures 4E and 4F and S3C and S3D). Despite the capacity to form 53BP1 and RIF1 foci, KB1P-G3 cells that were depleted of CTC1 restored IR-induced RAD51 focus formation, whereas γH2AX transfected control cells were deficient for this activity (Figures 4G and S3E). Similar conclusions were obtained when DNA damage was induced by treatment with 500 nM olaparib for 24 hr (Figures S3A and S3F–S3M). As expected, PARPi treatment resulted in more heterogeneous DNA damage induction compared with IR because PARPi inhibition primarily exerts its cytotoxic effects during replication.

We then tested whether CTC1 loss resulted in productive HR events in conditional BRCA1-deficient R26CreERT2;Brc11Sco1/1; Pim11–SRR–GFP/wt mESC cells carrying a stably integrated DR-GFP reporter (Bouwman et al., 2013). These cells were transfected to transiently express mCherry and I-SceI, and the percentage of mCherry/GFP double-positive cells was quantified by fluorescence-activated cell sorting (FACS) 24 hr later. Switching of the conditional Brc11Sco1 allele impaired HR activity, which was partially rescued upon deletion of the CST complex (Figures S3N and S3O).

Together, these data support a role for CTC1 as a resection antagonist acting on non-telomeric DSBs and as a mediator of the HR defect in BRCA1-deficient cells.

CTC1 Facilitates c-NHEJ-Mediated Repair at Telomeric and Non-Telomeric DSBs

It was previously shown that 53BP1, RIF1, and REV7/MAD2L2 antagonize resection and promote c-NHEJ (Boersma et al., 2015; Bouwman et al., 2010; Bunting et al., 2010; Chapman et al., 2013; Di Virgilio et al., 2013; Escribano-Díaz et al., 2013; Xu et al., 2015; Zimmermann et al., 2013). However, this is not a universal phenotype for resection antagonists because it is not shared by HELB (Tkac et al., 2013). We therefore sought to determine whether CTC1 affects NHEJ activity. First, we used Terf2–/–;Trp53–/– mouse embryonic fibroblasts (MEFs) that express a temperature-sensitive TRF2Ile468Ala mutant (TRF2ts) (Ko et al., 2013). TRF2ts are functional and maintain intact TRF2-protected telomeres at 32 °C, but this dissociates from telomeres at 37°C–39°C, inducing a DDR response and end-to-end chromosome fusions (Konishi and de Lange, 2008). TRF2ts is functional and maintains intact TRF2-protected telomeres at 32°C, but this dissociates from telomeres at 37°C–39°C, inducing a DDR response and end-to-end chromosome fusions (Konishi and de Lange, 2008). It was previously demonstrated that these fusions are driven by c–NHEJ and can be rescued by deletion of RNF8, DNA ligase IV, or REV7/MAD2L2 (Boersma et al., 2015; Celli and de Lange, 2005; Peuschel and Jacobs, 2011; Smogorzewska et al., 2002).

We depleted CTC1 in TRF2ts MEFs grown under permissive conditions (Figure 5A), which did not affect cell cycle distribution (Figures S4A and S4B). Cells were then grown at the non-permissive temperature (39°C) for 24 h to uncap telomeres and induce a DDR response prior to harvesting metaphase spreads for telomere fluorescence in situ hybridization (FISH). Although chromosome fusions were readily observed in control cells upon temperature-induced TRF2 inactivation, this was significantly reduced in Ctc1-mutated cells (Figures 5B and 5C; Figures S4C–S4E). In line with this finding and with NHEJ being inhibited by long ssDNA overhangs, it was previously shown that depletion of CTC1 increased ssG overhang length (Chen et al., 2012; Gu et al., 2012).

We next assessed whether CTC1 depletion in mouse CH12 B cells affects the ability to undergo class switch recombination (CSR) as a measure for non-telomeric c–NHEJ capacity (Mura-matsu et al., 2000). CH12 cells were transfected with Ctc1-targeting CRISPR/SpCas9 constructs and subcloned to obtain Ctc1-mutated CH12 cell clones. Notably, only 2 of 96 tested clones showed heterozygous Ctc1 allele disruption, and no homozygous knockouts were obtained (Figures S4F and S4G), raising the possibility that complete loss of CTC1 is lethal in CH12 cells. Wild-type and heterozygous Ctc1 knockout clones were subsequently stimulated with CD40Ab, interleukin-4 (IL-4), and transforming growth factor β-1 (TGF-β1, CD40Ab, IL-4, and TGFβ-1 [CTT]) to induce CSR from immunoglobulin M (IgM) to IgA, which was monitored by flow cytometry. Interestingly, heterozygous knockout of Ctc1 significantly diminished CSR in both clones (Figures 5D and 5E). We therefore conclude that CTC1 facilitates DSB repair via c–NHEJ at both telomeric and non-telomeric regions.

Depletion of CTC1 Mediates PARPi Resistance in the KB1P Mouse Model

Last, we explored the in vivo effects of CTC1 on the treatment response of BRCA1-deficient tumors to PARPi inhibition. We analyzed whether Ctc1 mRNA expression levels were altered in our previously generated collection of BRCA1- and p53-deficient KB1P and KB1PM mouse mammary tumors with acquired resistance to PARP inhibition (Jaspers et al., 2013). In total, this collection comprises 60 treatment-naive tumors and 85 matched PARPi-resistant tumors derived from 23 unique donors. To examine the expression levels of Ctc1 in treatment-naive and PARPi-resistant tumors, we produced RNA sequencing (RNA-seq) data for all tumors (E.G., unpublished data) and obtained the normalized expression values using edgeR (Robinson et al., 2010). We observed that the expression of Ctc1 is significantly downregulated in PARPi-resistant tumors compared with naive tumors (p = 6.34 × 10−4) (Figure 6A). Moreover, in tumors for which copy number variation by sequencing (CNVseq) data were available, CTC1 mRNA downregulation correlated with CNV loss (Figures S5A and S5D). Although a similar correlation was observed for STN1 and TEN1, these factors were not significantly downregulated in resistant tumors (Figures S5B, S5C, S5E, and S5F).

Finally, we used mammary tumor organoid technology (Duarte et al., 2018) to perform an in vivo intervention study with the PARPi olaparib in mice carrying tumors derived from isogenic KB1P organoids with or without disruption of Ctc1. For this purpose, KB1P4 organoids, derived from a KB1P mammary tumor, were cultured ex vivo and co-transduced with lentiviruses produced from pCMV–SpCas9 and pLenti–sgCtc1–tetR–T2A–Puro vectors. Control organoids were generated by co-transduction with pCMV–SpCas9 and pLenti– sgNT–tetR–T2A–Puro lentivirus encoding a non-targeting sgRNA (Figure 6B). The transduced KB1P4 tumor organoids were orthotopically transplanted in mice that were left untreated or treated daily with the PARPi olaparib for 56 consecutive days when tumors reached a size...
of 50–100 mm³. As expected, the Ctc1 target site was efficiently disrupted in tumors derived from KB1P4 organoids transduced with pCMV-SpCas9 and pLenti-sgCtc1-tetR-T2A-Puro (Figures 6C and 6D). Although KB1P4 control tumors only relapsed after treatment was stopped, CTC1-depleted tumors relapsed during treatment, resulting in accelerated mammary tumor-related death (median latencies: 39 days for sgCtc1_2 and 42 days for sgCtc1_3 cohorts compared with 73 days for control animals; log rank test, p = 0.0019 and p = 0.0086, respectively; Figure 6E). These data confirmed that depletion of CTC1 confers PARPi resistance in BRCA1-deficient tumors in vivo.

**DISCUSSION**

In this study, we show that loss of the CST complex members CTC1, STN1, and TEN1 induces PARPi resistance in tumors with irreversible loss of function of BRCA1. Our data highlight the CST complex as a pathway for tumor cells to escape the synthetic lethal effects of PARPi by restoring HR independently of BRCA1. In particular, we demonstrate that the underlying mechanism is a restoration of end resection of DSBs. Together, our findings demonstrate that the CST complex contributes to the regulation of DNA end stability not only at telomeres but also at non-telomeric DSBs.

We and others have recently shown that the 53BP1-RIF1-REV7/MAD2L2 pathway is crucial for blocking end resection of DSBs (Boersma et al., 2015; Bouwman et al., 2010; Bunting et al., 2010; Chapman et al., 2013; Di Virgilio et al., 2013; Escribano-Diaz et al., 2013; Xu et al., 2015; Zimmermann et al., 2013). However, it has remained elusive how DNA end stability is regulated by 53BP1-RIF1-REV7/MAD2L2 because none of these factors have been shown to contain direct DNA binding capacity and do not contain DNA processing activities. Our finding that the CST complex functions as a resection antagonist at
DSBs sheds light on this puzzle. The CST complex is an RPA-like complex that can directly bind ssDNA via multiple OB folds (Miyake et al., 2009). In collaboration with the laboratory of Dan Durocher, we recently identified another RPA-like complex, the Shieldin (SHLD) complex, which is composed of SHLD1 (C20ORF196), SHLD2 (FAM35A), SHLD3 (FLJ26957/CTC-534A2.2), and REV7/MAD2L2, as a downstream effector of 53BP1 in DSB repair (unpublished data). Hence, in addition to RPA and the SHLD complex, the CST complex is another trimeric complex that contains direct DNA binding capacity and affects DSB end stability. How these three complexes are recruited to DSBs in time and space remains to be elucidated. Possibly, RPA, SHLD, and CST compete for ssDNA at resected DSBs or collapsed forks to either promote or antagonize HR. Not mutually exclusive with this model, it is conceivable that these complexes might contain specialized functions dependent on the ssDNA substrate since the CST complex has been reported to preferentially bind to and promote melting of G-rich regions and G4-quadruplexes (Bhattacharjee et al., 2017; Lue et al., 2013).

Future work is also required to elucidate whether these complexes form the final step in the regulation of DSB end stability (for instance, through steric hindrance) or whether additional downstream factors are involved. Intriguingly, the CST complex has been described to buffer resection at telomeres via POLA-dependent fill-in DNA synthesis. This buffering activity might fine-tune the length of ssDNA around the DSB, which is vulnerable for nucleolytic degradation, and it might provide a rescue mechanism in case HR cannot be completed.

The identification of the CST complex as a mediator of PARPi response in BRCA1-deficient tumors might also have clinical implications because loss-of-function mutations in the CST-encoding genes are predicted to cause clinical PARPi resistance. Moreover, we expect that these alterations provide therapeutic vulnerabilities because we recently found that deletion of the 53BP1-dependent DNA repair pathway enhances sensitivity to IR (M.B., unpublished data).

EXPERIMENTAL PROCEDURES

Cell Culture and Gene Editing
The KB1P-G3 cell line was previously established from a K14cre;Brca1F/F;Trp53F/F (KB1P) mouse mammary tumor and cultured as described by Jaspers et al. (2013). The KB2P-3.4 cell line was previously established from a K14cre;Brcal2F/F;Trp53F/F (KB2P) mouse mammary tumor and cultured as described by Evers et al. (2008). The KB1P4 3D tumor organoid line was previously established from a Brca10/C0;p530/C0 mouse mammary tumor and cultured as described by Duarte et al. (2018). Further in vitro culture details and gene editing details are provided in the Supplemental Experimental Procedures.

Plasmids
Plasmids and cloning methods are provided in the Supplemental Experimental Procedures.

PARPis
Olaparib (CAS 763113-22-0) and AZD2461 (CAS 1174043-16-3) were synthesized by and purchased from Syncom (Groningen, the Netherlands). Talazoparib was purchased from Selectchem (catalog no.S7048).
Genomic DNA Isolation, PCR Amplification, and TIDE Analysis
Allele modification frequencies were quantified from genomic DNA isolated from tumor and cell line samples using Gentra Puregene (QIAGEN) according to the manufacturer’s protocol. Target loci were amplified by PCR and submitted for Sanger sequencing to confirm target modification using the TIDE algorithm (Brinkman et al., 2014). Parental cells were used as a reference sequence. PCR primer sequences are provided in Table S3. Further details are provided in the Supplemental Experimental Procedures.

CRISPR Library Screens
Screening details are provided in the Supplemental Experimental Procedures.

Alpha Track Assay
Experiments were performed as described previously (Xu et al., 2015) with minor modifications. Details are provided in the Supplemental Experimental Procedures.

Focus Formation Experiments
RAD51 immunofluorescence in CRISPR/SpCas9-transfected KB1P-G3 cells was performed as described previously with minor modifications (Xu et al., 2015). Details are provided in the Supplemental Experimental Procedures.

DR-GFP
The DR-GFP was performed as described previously (Bouwman et al., 2013). Genes were targeted using the pLentiCRISPRv2 system containing the indicated sgRNAs.

Assessment of Telomere NHEJ
Trt2+/−;Trp53−/−;TRF2ts (TRF2ts) MEFs were described before (Peuscher and Jacobs, 2011), and metaphase chromosome analysis was done as described before (Boersma et al., 2015). Details are provided in the Supplemental Experimental Procedures.

CSR Assay
Immunoglobulin CSR was performed as described previously (Xu et al., 2015). Details are provided in the Supplemental Experimental Procedures.

Generation of RNA-Seq Data
To determine the effects of Ctc1, Ten1, and Snt1 on PARPi treatment in vivo, we used our RNA-seq dataset generated from a cohort of PARPi-naive and -resistant KB1P and KB1PM tumors (Jaspers et al., 2013; E.G., unpublished data). Further details are provided in the Supplemental Experimental Procedures.

Generation of CNV Sequencing Data
Genomic DNA was isolated from a subset of matched naive-and resistant KB1P-derived fresh-frozen tumor material using standard phenol:chloroform extraction (Jaspers et al., 2013; E.G., unpublished data). Further details are provided in the Supplemental Experimental Procedures.

In Vivo Studies
All animal experiments were approved by the Animal Ethics Committee of the Netherlands Cancer Institute (Amsterdam, the Netherlands) and performed in accordance with the Dutch Act on Animal Experimentation (November 2014). Tumor organoids were allografted in 6- to 9-week-old female mice as described previously (Duarte et al., 2018) with minor modifications. Further details are provided in the Supplemental Experimental Procedures.

Quantification and Statistical Analysis
Statistical differences were calculated in GraphPad Prism using Student’s t tests. Statistical significance in Figure 2F was calculated by one-way ANOVA and post hoc Dunnett’s correction for multiple comparisons and in Figure 2G by one-way ANOVA and post hoc Dunnett’s correction for multiple comparisons. Statistical differences in Figures 4D–4G and Figures S3F–S3M were calculated by Kruskal-Wallis non-parametric test and post hoc Dunnett’s correction for multiple comparisons. Statistical differences in Figure 6E were calculated by log rank Mantel-Cox test. Significance is as follows: p > 0.05, not significant (n.s.); *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.0001 unless otherwise stated in the figure legends. Original data files used to prepare the figures in this manuscript have been deposited in Mendeley Data and are available at https://doi.org/10.17632/6wyzygw828k.1.

Contact for Reagent and Resource Sharing
Further information and requests for resources and reagents should be directed to and will be fulfilled by S.R. (sven.rottenberg@vetsuisse.unibe.ch).

DATA AND SOFTWARE AVAILABILITY
The accession number for the raw data of RNA-seq and CNV sequencing reported in this paper is European Nucleotide Archive (ENA): PRJEB25803.

SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures, five figures, and three tables and can be found with this article online at https://doi.org/10.1016/j.celrep.2018.04.046.

ACKNOWLEDGMENTS
We wish to thank Piet Borst for critical reading of the manuscript, the members of the Preclinical Intervention Unit of the Mouse Clinic for Cancer and Aging (MCCA) at the Netherlands Cancer Institute (NKI) for their technical support with the animal experiments, and Julian R. de Ruiter for assistance with bioinformatic analysis. We are grateful to the NKI animal facility, digital microscopy facility, flow cytometry facility, and genomics core facility for their excellent service. Financial support came from the Dutch Cancer Society (KWF 2011-5220 and 2014-6532 to S.R. and J.J.), the Netherlands Organization for Scientific Research (VICI 91814643, NGI 93512009, Cancer Genomics Netherlands, and a National Roadmap Grant for Large-Scale Research Facilities to J.J. and STW 13577 to D.C.v.G.), the Swiss National Science Foundation (310030_168869 to S.R.), the Swiss Cancer League (KLS-4282-08-2017 to S.R.), the European Union (ERC StG 311565 to J.J.L.J., ERC CoG 681572 to S.R., and ERC Synergy Grant 319661 to J.J.), Cancer Research UK (CRUK/A14278 to C.J.L.), and a Breast Cancer Now Program Grant (CTR-Q4-Y2 to C.J.L.). R.C. and H.G. are supported by Cancer Research UK (C52690/A19270) and MRC (MR/M009971/1) grants, respectively, and a Wellcome core award (090532/Z/09/Z).

AUTHOR CONTRIBUTIONS

DECLARATION OF INTERESTS
C.J.L. is a named inventor on patents describing the use of PARP inhibitors and stands to gain as part of the ICR’s “Rewards to Investors” scheme.

REFERENCES


